{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:58:52Z","timestamp":1791219532310,"version":"4.1.0"},"reference-count":10,"publisher":"American Veterinary Medical Association (AVMA)","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"sc_a1\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe clinical outcomes and adverse events in dogs with B-cell lymphoma treated with adoptive T-cell therapy (ACT) following cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a2\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medical records of 82 dogs with B-cell lymphoma that received ACT following CHOP chemotherapy between 2017 and 2025 were retrospectively reviewed. Overall survival was defined as the time from lymphoma diagnosis to death from any cause or last follow-up. Post-ACT survival was defined as the time from first ACT infusion to death from any cause or last follow-up. Time to next anti-lymphoma treatment was defined as the time from first ACT infusion to initiation of subsequent lymphoma-directed therapy. Survival outcomes were estimated using Kaplan-Meier analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a3\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>82 dogs met inclusion criteria. Median overall survival from diagnosis was 660 days (95% CI, 539 to 781 days). Median post-ACT survival was 368 days (95% CI, 261 to 474 days), and median time to next anti-lymphoma treatment was 317 days (95% CI, 284 to 350 days). Adoptive T-cell therapy was generally well tolerated following CHOP chemotherapy. Adverse events occurred in 5% (4 of 82) of dogs; most were grade 1 or 2, with 1 grade 3 event reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a4\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical outcomes varied among dogs with B-cell lymphoma treated with ACT following CHOP chemotherapy. Adoptive T-cell therapy was generally well tolerated, with adverse events reported in 4 of 82 dogs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sc_a5\">\n                    <jats:title>Clinical Relevance<\/jats:title>\n                    <jats:p>This study describes clinical outcomes and adverse events in 82 dogs with B-cell lymphoma that received ACT following CHOP chemotherapy. These findings provide clinical data on the use of ACT in this patient population and may inform the design of prospective controlled studies evaluating ACT in canine B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2460\/javma.26.05.0419","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:23:20Z","timestamp":1791217400000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes were evaluated in 82 dogs with B-cell lymphoma treated with adoptive T-cell therapy following cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy"],"prefix":"10.2460","author":[{"given":"Theresa E.","family":"Westfall","sequence":"first","affiliation":[{"name":"Aurelius Biotherapeutics, Bellingham, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Impellizeri","sequence":"additional","affiliation":[{"name":"Veterinary Oncology Services, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"key":"B1","series-title":"Withrow and MacEwen\u2019s Small Animal Clinical Oncology","first-page":"668","article-title":"Hematopoietic tumors","author":"Vail DM","year":"2020","unstructured":"Vail DM, Young KM. Hematopoietic tumors. In: Vail DM, Thamm DH, Liptak JM, eds. Withrow and MacEwen\u2019s Small Animal Clinical Oncology. 6th ed. Elsevier; 2020:668\u2013772."},{"issue":"1","key":"B2","series-title":"Vet Comp Oncol","first-page":"E159","article-title":"Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma","volume":"16","author":"Childress MO","year":"2018","unstructured":"Childress MO, Ramos-Vara JA, Ruple A. Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma. Vet Comp Oncol. 2018;16(1):E159\u2013E168. doi:10.1111\/vco.12364"},{"key":"B3","series-title":"Sci Rep","first-page":"249","article-title":"Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy","author":"O\u2019Connor CM","year":"2012","unstructured":"O\u2019Connor CM, Sheppard S, Hartline CA, et al. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep. 2012;2:249. doi:10.1038\/srep00249"},{"issue":"10","key":"B4","series-title":"Cancer Immunol Immunother","first-page":"1819","article-title":"Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma","volume":"61","author":"Munger CM","year":"2012","unstructured":"Munger CM, Hegde GV, Weisenburger DD, et al. Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma. Cancer Immunol Immunother. 2012;61(10):1819\u20131832. doi:10.1007\/s00262-012-1229-1"},{"issue":"4","key":"B5","series-title":"Vet Comp Oncol","first-page":"417","article-title":"Veterinary cooperative oncology group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1","volume":"14","year":"2016","unstructured":"Veterinary cooperative oncology group\u2014common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol. 2016;14(4):417\u2013446. doi:10.1111\/vco.283"},{"issue":"3","key":"B6","series-title":"Animals (Basel)","first-page":"391","article-title":"Canine multicentric lymphoma: diagnostic, treatment, and prognostic insights","volume":"15","author":"Rocha MCP","year":"2025","unstructured":"Rocha MCP, Ara\u00fajo D, Carvalho F, et al. Canine multicentric lymphoma: diagnostic, treatment, and prognostic insights. Animals (Basel). 2025;15(3):391. doi:10.3390\/ani15030391"},{"issue":"2","key":"B7","series-title":"Vet Comp Oncol","first-page":"147","article-title":"Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol","volume":"14","author":"Curran K","year":"2016","unstructured":"Curran K, Thamm DH. Retrospective analysis for treatment of na\u00efve canine multicentric lymphoma with a 15-week, maintenance-free CHOP protocol. Vet Comp Oncol. 2016;14(2):147\u2013155. doi:10.1111\/vco.12163"},{"issue":"1","key":"B8","series-title":"Vet Comp Oncol","first-page":"28","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2013a veterinary cooperative oncology group (VCOG) consensus document","volume":"8","author":"Vail DM","year":"2010","unstructured":"Vail DM, Michels GM, Khanna C, et al. Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2013a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. 2010;8(1):28\u201337. doi:10.1111\/j.1476-5829.2009.00200.x"},{"issue":"1","key":"B9","series-title":"Cancer Control","first-page":"1073274818789355","article-title":"Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database","volume":"25","author":"Agarwal P","year":"2018","unstructured":"Agarwal P, Moshier E, Ru M, et al. Immortal time bias in observational studies of time-to-event outcomes: assessing effects of postmastectomy radiation therapy using the National Cancer Database. Cancer Control. 2018;25(1):1073274818789355. doi:10.1177\/1073274818789355"},{"issue":"6","key":"B10","series-title":"J Vet Intern Med","first-page":"3193","article-title":"Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: a European multicenter retrospective cohort study","volume":"38","author":"Hawkes C","year":"2024","unstructured":"Hawkes C, Morris J, Bavcar S, et al. Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: a European multicenter retrospective cohort study. J Vet Intern Med. 2024;38(6):3193\u20133205. doi:10.1111\/jvim.17222"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.05.0419\/javma.26.05.0419.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/aop\/javma.26.05.0419\/javma.26.05.0419.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:23:21Z","timestamp":1791217401000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/aop\/javma.26.05.0419\/javma.26.05.0419.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":10,"URL":"https:\/\/doi.org\/10.2460\/javma.26.05.0419","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,5]]}}}